Key result
IV FR167653 before coronary occlusion reduces infarct size in rats with ischemia-reperfusion injury.
Why the study?
Does FR167653 reduce infarct size and inflammatory cytokine expression in a rat model of myocardial ischemia-reperfusion injury?
Does FR167653 reduce infarct size and inflammatory cytokine expression in a rat model of myocardial ischemia-reperfusion injury?
Inhibition of inflammatory cytokines by FR167653 effectively reduces myocardial ischemia-reperfusion injury in a rat model.
Answers are grounded in this paper and cite their sources.
Should not yet change reperfusion practice; leaves open translation of cytokine inhibition to human myocardial infarction.
FR167653 inhibits the production of inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) in human monocytes in a dose-dependent manner. We examined the effects of FR167653 on the propagation of myocardial infarction resulting from coronary occlusion-reperfusion and the time course of expression of these cytokines in myocardial tissue in rats. Myocardial infarction was induced by coronary ligation for 20 minutes followed by 2 hours of reperfusion. Although hemodynamic parameters did not differ significantly during coronary occlusion-reperfusion, the size of the infarct was significantly reduced by intravenous administration of FR167653 before occlusion (p < 0.01). mRNA levels of IL-1beta and TNF-alpha assessed by the reverse-transcriptase polymerase chain reaction method were significantly increased during coronary occlusion-reperfusion in the ischemic myocardium. Treatment with FR167653, however, significantly reduced the increased expression of these cytokines. These results indicate that the expression of inflammatory cytokines increases in the ischemic-reperfused myocardium and that the inhibition of the increased expression of cytokines by FR167653 effectively reduces myocardial ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Hoshida et al. (2000) studied Myocardial ischemia-reperfusion injury. FR167653 was evaluated on Infarct size (p=<0.01). Intravenous administration of FR167653 before coronary occlusion reduced infarct size in rats subjected to ischemia-reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: